Published 2 years ago

FDA approves drop to lower IOP in patients with glaucoma

Summary by Ground News

Santen and UBE announced the FDA approval of Omlonti for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension. The FDA granted the approval on Sept. 22, according to the agency's website. The active ingredient, omidenepag isopropyl, is a relatively selective prostaglandin EP2 receptor agonist.

0 Articles

All

Left

Center

Right

Healio

FDA approves drop to lower IOP in patients with glaucoma

Santen and UBE announced the FDA approval of Omlonti for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.

2 years ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.